



Wednesday, March 25, 2020 at 1:00 p.m. ET/12:00 p.m. CT

Stephens is hosting a conference call for institutional investors with Repligen CEO, Tony Hunt & CFO, Jon Snodgres. The call will be a high level fireside chat discussing RGEN's business followed by the opportunity for investor Q&A.



**Repligen** is a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. RGEN's revenue is diversified across product categories (filtration, chromatography, protein A, analytics, etc.) and across biologic drug end markets (monoclonal antibodies, recombinant proteins, cell/gene therapy, vaccines, etc.).

**Conference call date and time subject to change. To join the call or to obtain more information, please contact your Stephens sales representative.**

---

**Wednesday, March 25, 2020 at 1:00 p.m. ET/12:00 p.m. CT**

### Topics of Discussion

- The fundamentals of the bioprocessing market and the growth outlook for RGEN's chromatography, filtration, analytics, and proteins segments
- Demand trends from biologics and cell/gene therapy end markets
- The outlook for M&A given a net cash position

---

### Conference Call Host

**Jacob Johnson, CFA**  
Research Analyst  
Diagnostics & Life Science Tools  
(615) 279-4355  
[jacob.johnson@stephens.com](mailto:jacob.johnson@stephens.com)

**Stephens**  
Capitalize on  
Independence®

[STEPHENS.COM](http://STEPHENS.COM)

**f in** 800-643-9691

©2020 STEPHENS INC., MEMBER NYSE, SIPC  
STEPHENS INC., 111 CENTER STREET, LITTLE ROCK, AR 72201

[UNSUBSCRIBE](#) [EMAIL PREFERENCES](#) [VIEW ONLINE](#)

This announcement has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets or developments referred to in the material. The research analyst principally responsible for preparation of this announcement has received compensation that is based on the firm's overall revenue which includes investment banking revenue. To access current disclosures for the companies in this announcement, clients should refer to <http://info.stephens.com/e/244892/sellside-disclosures-action/vqjpy7/354033600?h=Qb31FRdTaAMc8CG@juu2D48nZqgCjMhII X3K13gIhgA> or contact your Stephens Inc. representative for additional information. Please also note that the announcement may include one or more links to external or third-party websites. Stephens Inc. has not independently verified the information contained on such websites and can provide no assurance as to the reliability of such information, and there can be no assurance that any opinions expressed on such websites reflect the opinions of Stephens Inc. or its management. Additional information available upon request.